ProShares Ultra Health Care (RXL) is an exchange-traded fund, or ETF — a basket of securities that trades on a stock exchange like a single stock. Unlike a conventional healthcare fund that aims to match its benchmark one-for-one, RXL is a leveraged product that seeks daily investment results corresponding to two times (2x) the daily performance of the S&P Health Care Select Sector Index. Investors who follow RXL are typically looking for a concentrated, amplified way to express a short-term view on the U.S. healthcare sector. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.
RXL's investment objective is to deliver roughly twice the daily return of the S&P Health Care Select Sector Index, before fees and expenses. The index is a capitalization-weighted benchmark that tracks U.S.-listed companies in the healthcare sector, spanning pharmaceuticals, biotechnology, health care equipment and supplies, health care providers and services, and life sciences tools.
The fund is issued by ProShares, a specialist provider of leveraged and inverse ETFs, and is managed by ProShare Advisors LLC. RXL was launched on January 30, 2007, making it one of the older leveraged healthcare products available to U.S. investors. It is passively managed, meaning portfolio managers aim to replicate the benchmark rather than pick individual winners.
To achieve its 2x daily target, the fund combines direct holdings of underlying stocks with financial derivatives — primarily total return swaps on the index — and short-term money market instruments. According to its issuer, the fund's market exposure is built through a blend of equity securities and swap agreements that together produce roughly 200% exposure to the index. This is a key part of the fund's investment strategy, and it explains why its portfolio looks different from a plain-vanilla healthcare ETF.
RXL's portfolio holdings reflect the composition of the S&P Health Care Select Sector Index, which is dominated by a handful of large pharmaceutical and healthcare conglomerates. The fund typically holds fewer than 100 positions and is considered non-diversified, meaning a small number of names can drive a large share of returns.
Among the index's largest constituents are household names such as Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), and UnitedHealth Group (UNH), along with Amgen, Thermo Fisher Scientific, Abbott Laboratories, Gilead Sciences, and Intuitive Surgical. Together, the top ten index constituents can account for well over half of the benchmark's weight.
The fund's sector exposure is essentially 100% healthcare, so its financial profile is tied closely to the performance of the broader healthcare industry rather than the wider market. Investors receive no meaningful diversification across other sectors.
RXL attracts attention primarily from traders and sophisticated investors who want amplified, short-term exposure to U.S. healthcare stocks. The healthcare sector is often viewed as a long-term growth theme driven by aging demographics, medical innovation, and steady demand for treatments and services — dynamics that can make it appealing during specific market conditions.
Because RXL targets 2x daily returns, it can magnify both gains and losses. This makes it a tool for expressing a directional view on healthcare over a single trading day, rather than a core long-term holding. The fund also provides a way to gain leveraged exposure without using margin, and it is among the few ETFs dedicated specifically to doubled healthcare-sector returns.
RXL carries several risks that set it apart from conventional ETFs. First, it is a leveraged fund, meaning daily losses can be roughly twice as large as the underlying index's decline. Second, because leverage resets each day, returns over periods longer than one day can diverge significantly from two times the index's cumulative return — a phenomenon known as compounding or "volatility decay." In choppy markets, this can erode long-term results even when the underlying index is roughly flat.
The fund is also concentrated in a single sector, so it is sensitive to healthcare-specific factors such as drug-pricing regulation, patent expirations, clinical trial outcomes, and policy changes. Its reliance on derivatives and swaps introduces counterparty risk, and its expense ratio of 0.95% is higher than that of many unleveraged healthcare ETFs. As a result, RXL is generally considered unsuitable for conservative or long-term investors and is intended for those who actively monitor their positions.
ProShares Ultra Health Care (RXL) stands out as a specialized, leveraged ETF that delivers two times the daily performance of the S&P Health Care Select Sector Index. Its appeal lies in amplified, single-day exposure to some of the largest U.S. healthcare companies, from drugmakers to medical-device and insurance leaders. At the same time, its daily-reset leverage, sector concentration, and reliance on derivatives make it a sophisticated instrument best suited to short-term traders rather than long-term investors. For those who understand these trade-offs, RXL remains a notable tool for gaining leveraged healthcare exposure.
In my view, tools like Tickeron’s AI Screener have become a regular part of how I evaluate leveraged products such as RXL. The platform lets me apply technical indicators, fundamentals, and industry filters to quickly compare opportunities across thousands of securities. I find it especially useful when assessing sector-specific ETFs or spotting patterns that align with a short-term trading thesis. It adds a data-driven layer without replacing traditional analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where RXL declined for three days, in 268 of 303 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
The 10-day RSI Indicator for RXL moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 25 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RXL as a result. In 78 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for RXL turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 40 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for RXL crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +0.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXL advanced for three days, in 276 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
RXL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 231 of 256 cases where RXL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows